Showing results (361-370 of 374) with videos related to

Sort By:
Pageof 38
Journal of the American Chemical Society|July 21, 2020
High-Resolution XFEL Structure of the Soluble Methane Monooxygenase Hydroxylase Complex with its Regulatory Component at Ambient Temperature in Two Oxidation StatesVivek Srinivas, Rahul Banerjee, Hugo Lebrette, et al.
Blood Cancer Journal|October 16, 2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaGliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, et al.
JAMA Oncology|January 6, 2017
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Blood Advances|February 24, 2023
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysisBrittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, et al.
Blood Cancer Journal|May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumOren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Pageof 38